Inspire Pharmaceuticals Inc

Inspire Pharmaceuticals — UBS Global Life Sciences Conference 2009

33 slides from Inspire Pharmaceuticals's conference presentation, Sep 22, 2009

  1. Slide 1: UBS Global Life Sciences Conference

    Exhibit 99.1 UBS Global Life Sciences Conference September 22, 2009

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, which convey management's expectations, beliefs, plans and objectives regarding future performance. These statements discuss matters that are not facts

  3. Slide 3: Robust Pipeline with Multiple Catalysts

    Robust Pipeline with Multiple Catalysts Multiple Novel Programs Three Ophthalmology Products Denufosol for cystic fibrosis in Phase 3 for bacterial Innovative $80-90 mm conjunctivitis ProlacriaTM for dry Late-Stage Revenue eye in Phase 3* Pipeline Stream*** for prevention of itching for blepharitis

  4. Slide 4: Novel Clinical Pipeline

    Novel Clinical Pipeline Pre-Clinical Phase 1 Phase 2 Phase 3 Prolacria TM for dry eye* Denufosol for cystic fibrosis AzaSite ® for blepharitis ** INS115644 for glaucoma INS117548 for glaucoma * NDA filed and received two approvable letters from FDA ** Currently approved for the treatment of bacteria

  5. Slide 5: Cystic Fibrosis: Life Threatening and Underserved

    Cystic Fibrosis: Life Threatening and Underserved Disease Quick Facts CF is caused by a genetic mutation that disrupts the CFTR protein, an ion channel, and leads to poorly hydrated lungs and severely impaired mucociliary clearance ~30,000 U.S. patients; 70,000 worldwide* Life expectancy: ~37 yrs* M

  6. Slide 6: Denufosol's Mechanism of Action Restores Mucosal Hydration and Mucociliary Clearance in CF

    Denufosol’s Mechanism of Action Restores Mucosal Hydration and Mucociliary Clearance in CF Inefficient Thickened Lung CFTR Bacterial Irreversible Ion Airway Structural Defect Colonization Inflammation Transport Secretions Damage Gene Therapy, Ion Transport Mucus Antibiotic Anti- Lung Potentiator/ Re

  7. Slide 7: Global Phase 3 Program with Denufosol for CF

    Global Phase 3 Program with Denufosol for CF O NH2 HN N O N O N O O O O O P O P O P O P O O - - - - O O O O O OH OH 4 Na + OH Two Phase 3 pivotal trials: TIGER-1 and TIGER-2 TIGER-1 met primary efficacy endpoint in 24-week placebo-controlled portion Showed increasing lung function in open-label 24-w

  8. Slide 8: Primary Efficacy Results from TIGER-1: Placebo-Controlled (ITT)

    Primary Efficacy Results from TIGER-1: Placebo-Controlled (ITT) Enrolled 352 patients with Mean (SE) Change in FEV 1 (mL) early stage CF lung disease (FEV1 75% predicted normal) and 5 years old 70 60 Met primary efficacy endpoint: change in FEV1 from baseline 50 to endpoint* 48 40 45 mL treatment ef

  9. Slide 9: Mean Change from Baseline FEV1

    Mean Change from Baseline FEV1 Mean (SE) Change from Baseline FEV1 (mL) 140 Denufosol 120 Placebo 100 80 60 40 20 0 -20 -40 0 4 12 24 28 36 48 Treatment Week CFB=Change from Baseline ITT Population # Values displayed are mean observed values at each time point without adjustment for discontinuations

  10. Slide 10: Mean Change from Baseline FEV1

    Mean Change from Baseline FEV 1 Mean (SE) Change from Baseline FEV1 (mL) 140 Denufosol-only, Open-label Phase Denufosol 120 Placebo 100 80 60 40 20 0 -20 -40 0 4 12 24 28 36 48 Treatment Week CFB=Change from Baseline ITT Population # Values displayed are mean observed values at each time point witho

  11. Slide 11: Mean Change from Baseline FEV1

    Mean Change from Baseline FEV 1 Mean (SE) Change from Baseline FEV1 (mL) 140 Denufosol-only, Open-label Phase Denufosol 120 Placebo Placebo Switched to Denufosol 100 80 60 40 20 0 -20 -40 0 4 12 24 28 36 48 Treatment Week CFB=Change from Baseline ITT Population # Values displayed are mean observed v

  12. Slide 12: TIGER-2 Phase 3 Clinical Trial (08-110)

    TIGER-2 Phase 3 Clinical Trial (08-110) Planned Trial Size: 450 R Primary Endpoint A Key Inclusion Criteria N Change in FEV1 in liters at Denufosol 60 mg 48-week endpoint FEV1 75% and 110% D TID predicted normal for age, O N = 225 gender and height M Age 5 or older I Secondary Endpoint Z Pulmonary e

  13. Slide 13: Dry Eye: Affects More Than 30 Million Patients Worldwide

    Dry Eye: Affects More Than 30 Million Patients Worldwide Disease Quick Facts Caused by environmental or genetic factors, aging/menopause, immune/inflammatory disease, lid margin disease, certain medications Disease of the tears and ocular surface that leads to instability of the tear film, symptoms

  14. Slide 14: Prolacria: Mechanism of Action for Dry Eye

    ProlacriaTM : Mechanism of Action for Dry Eye Mucin, aqueous Internally developed & lipid layers P2Y2 agonist Receptor activation results in increased Lipid intracellular calcium secretion concentration, which triggers a series of intracellular events resulting in mucosal surface secretion Water Pro

  15. Slide 15: Phase 3 Program with Prolacria for Dry Eye

    Phase 3 Program with Prolacria™ for Dry Eye O O HN HN O N O N O O O O O P O P O P O P O O - - - - O O O O O OH OH 4 Na + OH OH Four Phase 3 clinical trials conducted to date Tolerability and safety profile similar to placebo Received two approvable letters from U.S. FDA Initiated additional Phase 3

  16. Slide 16: Clearing of Central Corneal Staining

    Clearing of Central Corneal Staining Proportion of all patients, regardless of baseline staining, that achieved clearing of central corneal staining (NEI score of 0) at Week 6 Endpoint in the Phase 3 environmental trials (Intent-to-Treat Population) 03-104 03-105 03-109 Placebo Prolacria Placebo Pro

  17. Slide 17: Clearing of Central Corneal Staining in Patients With Baseline Score of 3

    Clearing of Central Corneal Staining in Patients With Baseline Central Corneal Staining Score of 3 Proportion of patients with a baseline NEI staining score of 3 in the central cornea that achieved clearing of central corneal staining (NEI staining score of 0) at Week 6 Endpoint in the Phase 3 envir

  18. Slide 18: Prolacria Phase 3 Environmental Clinical Trial (03-113)

    Prolacria™ Phase 3 Environmental Clinical Trial (03-113) Planned Trial Size: 450 R Primary Endpoint A N Prolacria Key Inclusion Criteria (diquafosol tetrasodium Proportion of subjects D ophthalmic solution 2%) receiving Prolacria that QID Corneal fluorescein staining O N = 225 achieve clearing of M

  19. Slide 19: Global Partnerships for Prolacria/DE-089

    Global Partnerships for Prolacria™/DE-089 Partnered with Allergan, Inc., a leading global ophthalmic company Inspire responsible for development and approval of Prolacria™ in the United States, with right to co-promote Allergan responsible for commercialization and all post-marketing activities in t

  20. Slide 20: AzaSite: Differentiated Ocular Anti-Infective

    AzaSite®: Differentiated Ocular Anti-Infective First ocular form of azithromycin AzaSite combines well-known, broad spectrum macrolide antibiotic, azithromycin (1%), with DuraSite® drug delivery technology Anti-inflammatory properties Approved by FDA in April 2007, with indication for treatment of b

  21. Slide 21: Recent Development in Ocular Antibiotic Market

    Recent Development in Ocular Antibiotic Market Current manufacturing supply shortage of erythromycin ophthalmic ointment CDC made the Generic macrolide antibiotic routinely used in neonates following for prophylaxis of ophthalmia neonatorum, a form of recommendation: bacterial conjunctivitis that ma

  22. Slide 22: Blepharitis: A New Potential Indication

    Blepharitis: A New Potential Indication Disease Quick Facts Common condition characterized by inflammation of the eyelids, which is often secondary to infection Often involves significant patient discomfort leading to associated ocular surface inflammation, chronic ocular irritation, unstable tear f

  23. Slide 23: Two-Week Phase 4 Trial in Posterior Blepharitis: Effect on Lid Margin Hyperemia

    Two-Week Phase 4 Trial in Posterior Blepharitis: Effect on Lid Margin Hyperemia 4.0 p < 0.001 Warm Compresses (WC) 3.0 AzaSite + WC 2.0 1.0 0.0 Baseline After 2 Weeks of Treatment 69% Improvement in Mean from Baseline with AzaSite ® vs. 10% with WC Alone (n=21) (0) Normal: no redness (3) Severe: inc

  24. Slide 24: Four-Week Phase 4 Trial in Anterior/Posterior Blepharitis

    Four-Week Phase 4 Trial in Anterior/Posterior Blepharitis AzaSite® 2 Wks After 4 Wks After After 4 Wks Baseline Dosing Dosing Dosing* Stopped* Stopped* Eyelid Itching 2.2 0.9 1.1 0.6 p<0.001 p<0.001 p<0.001 0.7 0.9 0.8 Foreign Body Sensation 2.2 p<0.001 p<0.001 p<0.001 Ocular Dryness 2.2 1.3 1.3 1.6

  25. Slide 25: AzaSite Phase 2 for Blepharitis Clinical Trials

    AzaSite® Phase 2 for Blepharitis Clinical Trials (044-101 and 044-102) Planned Trial Size: 300 R A AzaSite N (azithromycin ophthalmic Endpoints Key Inclusion Criteria D solution) 1% 1 drop BID for 2 days, then O 1 drop QD for remainder Signs and symptoms of Have current diagnosis M N = 150 of blepha

  26. Slide 26: Glaucoma: Largest Ophthalmic Market

    Glaucoma: Largest Ophthalmic Market Disease Quick Facts Glaucoma is the leading cause of blindness in the world and the leading cause of preventable blindness in the U.S., according to the World Health Organization Glaucoma is a group of eye diseases that gradually reduces the field of vision A vari

  27. Slide 27: Glaucoma Program Update

    Glaucoma Program Update Novel approach to lowering intraocular pressure (IOP) by targeting primary outflow pathway (trabecular meshwork) Top-line Phase 1 clinical trial results in patients with elevated IOP INS115644 (Latrunculin B) – observed dose-dependant IOP-lowering effects in 56 randomized sub

  28. Slide 28: Financing Summary

    Financing Summary Raised $115 million in common stock offering in August 2009 Financing fully funds current strategic plan Provides strong foundation to advance Company to the next level Enables a rapid succession of multiple catalysts Top-line clinical results in four programs within two years Thre

  29. Slide 29: Current Financial Summary

    Current Financial Summary ~ $150 MM pro forma cash and investments balance, based on 6/30/09 balance plus $109 MM net proceeds from recent common stock offering 82.3 million common shares outstanding after common stock offering 2009 guidance reaffirmed on 07/31/09 Revenue - $80-90 mm Expenses - $120

  30. Slide 30: Growing Stream of Revenues

    Growing Stream of Revenues Inspire Receives Revenues from Three Products* ($ Millions) Inspire Has Achieved Double-Digit Annual Growth Each Year $80-90** $71 45% increase $49 $37 31% increase 59% increase $23 110% increase $11 2004 2005 2006 2007 2008 2009 Guidance * Inspire receives revenues relate

  31. Slide 31: Multiple Significant Events Over the Next Two Years

    Multiple Significant Events Over the Next Two Years Denufosol for Cystic Fibrosis – Phase 3 Complete enrollment in TIGER-2 CF trial (year-end 2009) Report top-line results of TIGER-2 CF trial Identify ex-North American partner for denufosol Prolacria TM for Dry Eye – Phase 3 Complete enrollment in P

  32. Slide 32: Inspire Summary

    Inspire Summary Vision to build long-term value Therapeutically focused with unique, innovative pipeline and products Recent financing fully funds current strategic plan and provides strong foundation for future growth Multiple upcoming catalysts Top-line clinical results in four programs within two

  33. Slide 33: UBS Global Life Sciences Conference

    UBS Global Life Sciences Conference September 22, 2009

Inspire Pharmaceuticals — UBS Global Life Sciences Conference 2009 on 6ix